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ntrusion Through
he Fragile Back Door
mmature Plaque Microvessels
s Entry Portals for Leukocytes
nd Erythrocytes in Atherosclerosis*
ebastian F. Mause, MD,†‡ Christian Weber, MD†
achen, Germany
arge and healthy human arteries possess in varying degrees
nourishing microvasculature, consisting of first- and
econd-order vasa vasorum, which is confined to the adven-
itia and outer media. However, as already noted in 1876 by
oester (1), atherosclerotic modified blood vessels are asso-
iated with an “ectopic” vascularization of the intima and
nner media. Barger et al. (2) proposed that proliferation of
he adventitial microvasculature into the intima enables
therosclerotic plaques to develop beyond a critical size by
upplying oxygen and nutrients. Morphometric analysis
dentified that the majority of intimal microvessels originate
ndeed from adventitial vasa vasorum, whereas microvessels
erived from the vessel lumen are rarely detectable, although
resent in particular in the shoulder region of atherosclerotic
esions (3,4).
See page 1517
The molecular mechanisms responsible for ectopic mi-
rovessel formation are related predominantly to tissue
ypoxia (5). Once vessel wall thickness exceeds a certain
epth as a consequence of, for example, intimal thickening,
xygen levels in the intima will be critically diminished.
lternatively, hypoxia might be present as a result of
receding dysfunction of the adventitial microvasculature.
ccordingly, increased neovascularization could be observed
n hypercholesteremic animal models before the establish-
ent of manifest vascular lesions and before impaired
asorelaxation in response to bradykinin (5,6). Hypoxia-
ependent neovascularization is significantly mediated by
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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hareholder of Carolus Therapeutics Inc., and has received funding from the German
esearch Foundation DFG.he hypoxia-inducible factor (HIF)-1, a transcription fac-
or that has been substantially detected in inflammatory and
ypoxic areas of human atherosclerotic lesions and that
romotes the expression of multiple genes controlling an-
iogenesis such as vascular endothelial growth factor
VEGF), angiopoietin (Ang)-2, nitric oxide synthase, and
atrix metalloproteinase-2 (7,8). Independent of hypoxia,
nflammatory reactions and oxidative stress may support
ctopic neovascularization and extensive vascular remod-
ling (9). It is believed that rather than being the
nitiators of the process, inflammatory cells would am-
lify and perpetuate the ongoing angiogenic process
riginally triggered by hypoxia. Possible mechanisms
nvolve augmented production of acidic fibroblast growth
actor and secretion of the chemokine interleukin-8 by
ctivated plaque macrophages, delivery of basic fibroblast
rowth factor by mast cells found in proximity to mi-
rovessels, or increased generation of reactive oxygen
pecies (9 –11).
The study by Sluimer et al. (12) in this issue of the Journal
hows that microvessel density in the adventitia and intima
ncreased with plaque progression in coronary arteries.
ntriguingly, an abnormality of intraplaque microvascular
ndothelial cells (ECs) with incomplete endothelial junc-
ions and membrane detachment could be identified. As in
ddition, altered ECs were spatially linked to monocyte and
ast cell accumulation, this study substantiates the concept
f leaky and dysfunctional plaque microvessels. According
o such a concept, these nascent vessels may constitute key
ntry points for cellular and soluble lesion components,
mplicating a permissive role of plaque microvessels for the
rogression of atherosclerosis. These portals may gain im-
ortance particularly in advanced lesions, because the dense
brous caps are practically not penetrable by blood cells.
ndeed, previous histopathological studies have shown a
lose association between areas of increased intimal vascu-
arization and accentuated accumulation of monocytes/
acrophages, mast cells, and T cells, indicative of ongoing
nflammatory reactions and leaky microvessels. This associ-
tion was shown to be prominent in patients with symp-
omatic atherosclerosis and in the shoulder regions of
laques, which are known to be prone to rupture (4,13,14).
n a molecular level, extravasation of inflammatory cells
rom plaque microvessels may be supported by modified
xpression of endothelial adhesion and junctional molecules.
t has been shown that vascular endothelial cadherin, which
s of pivotal importance for the control of endothelial cell
ontacts and negatively interferes with VEGF-stimulated
ell proliferation, is down-regulated within intimal mi-
rovessels (15). This was associated with a discontinuity of
he endothelial lining and increased recruitment of inflam-
atory cells. Moreover, expression of intercellular adhesion
olecule-1, vascular cell adhesion molecule (VCAM)-1,
nd E-selectin was found to be intensified on ECs of the
ntimal microvasculature (9). Further studies are needed to
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olecular level and to more precisely render the determi-
ants of microvessel leakiness, in particular junctional mol-
cules regulating endothelial permeability and leukocyte
ransmigration (16).
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Figure 1 Immaturity of Plaque Microvessels
Plaque microvessels show a compromised structural integrity and a modified expre
inflammatory cells and soluble factors as well as the occurrence of microhemorrha
plaque vulnerability. For further details, please see text. Ang  angiopoietin; FGF 
hypoxia-inducible factor; PDGF  platelet-derived growth factor; VE  vascular endSimilar to leukocytes, a temporospatial association of
laque microvessels with extravasation of erythrocytes has
een documented, consistent with intimal neoangiogenesis
s a source for focal intraplaque hemorrhages. These micro-
emorrhages and subsequent phagocytosis of cholesterol-
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profile of adhesion and junctional molecules, thus permitting extravasation of
he resulting reactive microenvironment may support further plaque growth and
blast growth factor; Hb  hemoglobin; HGF  hepatocyte growth factor; HIF 
l; VEGF  vascular endothelial growth factor. Figure illustration by Rob Flewell.ssion
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Aberrant Plaque Microvessels Promoting Cell Influx April 28, 2009:1528–31ich erythrocytes are related to an increase in free cholesterol
nd lipid peroxidation within the plaque, hemoglobin re-
ease and iron deposition contributing to oxidative stress, as
ell as activation of macrophages linked to the release of
issue lytic factors (17). Together with a local enrichment of
EGF and ongoing inflammation, this can create a highly
eactive microenvironment, which is counteractive to effi-
ient maturation of nascent plaque microvessels. It is tempt-
ng to speculate that such a cycle of events with hypoxia,
ccelerated angiogenesis, local inflammation, and matrix
emodeling finally promotes plaque expansion and plaque
ulnerability.
Mural cells, in particular pericytes, may play a crucial role
n microvascular maturation, stabilization, and function via
xtensive reciprocal communication with endothelium cells.
or instance, Ang-1, expressed substantially by pericytes,
as been shown to mediate vessel maturation via interaction
ith Tie-2 (18). Furthermore, the transforming growth
actor- signaling machinery may assist in vascular smooth
uscle cell differentiation and platelet-derived growth fac-
or released from ECs can support proliferation and migra-
ion of mural cells during vessel wall stabilization (19).
crutinizing the presence of mural cells around microves-
els, Sluimer et al. (12) surprisingly observed no differences
n the scarce mural cell coverage between normal and
therosclerotic coronary arteries. Together with the docu-
ented lack of regional disparity within the same artery,
hese results may question the common understanding of
ural cells crucially supporting vascular integrity. However,
uch a conclusion should be drawn with caution, because
ata on mural cell coverage of microvessels is not fully
onsistent (13), and concerted studies evaluating the molec-
lar and functional properties of mural cells communicating
ith the microvascular endothelium are lacking in the
ontext of atherosclerosis (Fig. 1).
Functional animal studies have corroborated the pro-
osed link between intimal neovascularization and athero-
clerosis; however, no consensus has yet emerged on the
ausality of such an association. It has been shown that
ndothelium-specific inhibitors of angiogenesis (endostatin,
NP-470) significantly reduced plaque area in hypercho-
esterolemic apolipoprotein (apo) E/ mice (20). Con-
ersely, administration of recombinant VEGF, known to
odulate vascular permeability, promoted atherosclerosis in
poE/apoB-100–deficient mice (21). Interestingly, most of
he subsequent small animal studies suggesting a proathero-
enic and destabilizing effect of VEGF failed to show an
ncreased angiogenesis in the vessel wall (9,11), indicative of
ngiogenic-independent effects of the dichotomous VEGF.
ccordingly, VEGF has been shown to trigger up-
egulation of endothelial VCAM-1 and redistribution of
latelet endothelial cell adhesion molecule-1, thus aug-
enting inflammatory leukocyte adhesion and transmigra-
ion (11). Of note, studies on VEGF and its receptors in
nimal models yielded contradictory findings with regard to
theroprogression, which may be partly reconciled by link-ng biological effects of VEGF to different concentrations
ithin the microenvironment (9,22). Whereas low VEGF
oncentrations may exert atheroprotective effects, higher
ocal VEGF levels can result in formation of aberrant and
eaky vessels.
Because of the emerging evidence linking ectopic neovas-
ularization and immature microvessels with atherosclerosis,
einforced inflammation, and plaque destabilization and
ecause of the promising results of antiangiogenic treatment
trategies in cancer disorders and macular degeneration
23,24), antiangiogenic therapy in atherosclerotic diseases
ecomes increasingly appealing. Keeping in mind the ad-
erse cardiovascular consequences of systemically applying
igh doses of the anti-VEGF antibody bevacizumab in
ancer patients, the establishment of a new therapeutic
aradigm in cardiovascular diseases targeting plaque micro-
asculature with the aim of decelerating or even inverting
laque growth and adverse inflammatory reactions de-
ands: 1) further evaluation of molecular determinants of
mmaturity and of the critical balance of proangiogenic and
ntiangiogenic factors in the plaque microenvironment;
) technical advances in noninvasive and invasive imaging
trategies for diagnosis, risk stratification, and treatment
urveillance; and 3) amelioration of application techniques
chieving site-specific delivery for agents that are angio-
odulating rather than antiangiogenic. The findings of
luimer et al. (12) corroborate the concept that the mere
nhibition of intimal neoangiogenesis should not be the
oncrete therapeutic goal, but rather the induction of
ccelerated microvessel maturation and vessel robustness. A
ormalized, less leaky vasculature, characterized by a quies-
ent endothelium, a restrictive basement membrane, and
ufficient coverage by pericytes, may establish a more favor-
ble microenvironment by diminishing extravasation of
nflammatory cells, deposition of lipoproteins, and the
ccurrence of adverse microhemorrhages and thus inter-
epting the vicious cycle leading to vascular remodeling and
laque destabilization. Possible strategies for curbing the
mmaturity of microvessels comprise a temporospatial
ontrol of VEGF levels, promotion of Ang-1–Tie-2
athway loops, facilitation of pericyte recruitment and
rganization, or therapy with progenitor cells giving rise
o smooth muscle-like cells (18,25,26).
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